Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theriva Biologics, Inc.TOVX · Entity 7919 | Chief Operating Officer | December 15, 2022 | December 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theriva Biologics, Inc.
Report date December 15, 2022 · Filed December 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2029-12-15 | Direct | 100,000 |
Reported balance
After 2022-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-15 · Grant · Acquired 100,000 · Balance 100,000 F1: These stock options vest pro rata on a monthly basis over 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest pro rata on a monthly basis over 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2022 Filed Dec 16, 2022 23:16 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-22-127971 · tm2232925-1_4seq1.xml · derivative · entry 1 Tufaro Francis · CIK 0001906510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-15 F1 · shares: These stock options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.